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Abstract: Poor solubility of active pharmaceutical ingredients (APIs) is a great challenge for
the pharmaceutical industry and, hence, drug nanocrystals are widely studied as one solution
to overcome these solubility problems. Drug nanocrystals have comparatively simple structures
which make them attractive for the formulation for poorly soluble drugs, and their capability to
improve the dissolution in vitro is easily demonstrated, but turning the in vitro superior properties
of nanocrystals to success in vivo, is often demanding: controlled (including enhanced) drug
dissolution followed by successful permeation is not guaranteed, if for example, the dissolved drug
precipitates before it is absorbed. In this review critical quality attributes related to nanocrystal
formulations from production to final product performance in vivo are considered. Many important
parameters exist, but here physical stability (aggregation tendency and solid state form), solubility
properties influencing dissolution and supersaturation, excipient use to promote the maintenance
of supersaturation, and finally the fate of nanocrystals in vivo are the main subjects of our focus.
Keywords: bioavailability; drug nanocrystals; permeation; precipitation; solubility; stability;
supersaturation
1. Introduction
Today one of the greatest challenges in drug delivery is the poor solubility of new chemical
entities: approximately seventy to ninety percent of new chemical entities are having solubility
issues [1]. In the Biopharmaceutics Classification System (BCS) drugs with poor solubility are
classified either as class II drugs, exhibiting poor solubility relative to their dose, or as BCS class
IV drugs, with both poor solubility and poor permeability. Solubility enhancement improves the
bioavailability of BCS class II drugs, but it may also help BCS class IV drugs; since permeation can be
enhanced via a higher concentration gradient between the gut and lumen.
One relatively simple approach to improve drug dissolution and solubility properties is
formulation as nanocrystals [2–4]. Drug nanocrystals are solid nanosized drug particles surrounded
by a stabilizer layer; sometimes they are also referred to as solid micelles. Typically, their size ranges
from approximately 200 to 800 nm, depending on the application [5]. The increased dissolution
rate is mainly due to the increased specific surface area, but with particle sizes under 1 µm the
saturated solubility is also increased (compared to thermodynamic solubility) and the diffusion layer
is thinner [4,6].
The selection of suitable stabilizers is crucial for successful nanocrystal formation. Surfactants or
polymers, such as polysorbates [7], poloxamers [6], cellulose derivatives [8,9], vitamin E TPGS [8] are
all commonly used as stabilizers. In addition, other excipient groups have been investigated for their
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suitability as stabilizers. For example, Azad et al. [10] studied the utilization of superdisintegrants
as stabilizers during milling in order to avoid using surfactants, but these are not commonly
used. One complicating point with surface-active stabilizers is that they often affect cell membrane
functionality. For example polysorbates can make membranes leakier [11] and stimulate P-gp
activity [12]. One example of the consequence of this is polysorbate 80 having been observed to
increase drug absorption through the sublingual mucosa [11]. Often, stabilizers also increase the
solubility of the drug material to some degree.
Though drug nanocrystals are called nanocrystals and are typically indeed crystalline, they may
also contain amorphous drug (in part or in whole), depending on the production technique [4].
Liquid-atomization based bottom-up techniques can often precipitate some amorphous material.
With other techniques, the product is most often crystalline [3,4], but polymorphic changes may take
place with all techniques, during nanocrystallization [13].
In vitro, fast dissolution is easily demonstrated with nanocrystalline formulations [14]. However,
turning this success into high bioavailability in vivo, is often challenging. Physical stability can
be problematic; small particles may aggregate, and even more challenging in vivo is to hinder
the reprecipitation which itself will inhibit drug permeation. We have recently demonstrated this
situation with itraconazole nanocrystals in oral drug delivery [15]. Nanocrystal-based itraconazole
capsule formulations, which were superior to marketed Sporanoxr granules in in vitro tests
were studied. In vivo, the relative bioavailability was only 40% of that of Sporanoxr. When
analyzing the in vivo pharmacokinetic profile of the nanocrystal formulations, the dissolution was
initially very fast. However, after an initial peak, the concentration rapidly decreased due to
precipitation/crystallization. Accordingly, the maintenance of the high supersaturated solution
concentration in vivo failed.
The itraconazole case described above is just one example that highlights the importance
of controlled drug dissolution followed by successful permeation and underlines the importance
of understanding critical quality attributes during the whole lifecycle of the nanocrystal from
crystallization to formulation to end product performance. In this article, critical quality attributes
related to production as well as final product performance in vivo with nanocrystalline products are
reviewed. There are many important properties, but perhaps the most important factors affecting the
success of nanocrystal products and thus discussed in detail in this review are: (i) physical stability
(aggregation tendency and solid state form); (ii) solubility (which itself influences dissolution and
supersaturation); and (iii) excipient selection and use together with promotion of supersaturation
maintenance. Lastly, the fate of nanocrystals in vivo is considered.
2. Properties of Nanocrystals
Characterisation of nanocrystals should consider the interrelated properties of solid state
(i.e., crystal form, degree of crystallinity), particle size and morphology, as well as surface/interaction
properties (adsorbed stabilizer, surface charge). Table 1 lists some useful characterisation methods,
the properties that they probe, as well as the nature of information obtained, and practical aspects of
each technique. In the following sections the critical properties of drug nanocrystals, that have been
ascertained with these characterization methods, are considered more deeply.
3. Solid State Properties
The solid state form (polymorphic crystal form, solvate (especially hydrate) form, degree of
crystallinity) affects the apparent solubility and hence dissolution rate. Therefore, it is crucial
to determine these properties in nanocrystals. Typically, the thermodynamically most stable
crystalline form is desirable to prevent the risk of solid state transformations during storage and/or
administration [16]. To increase dissolution and bioavailability of nanocrystals, it is possible to
prepare the nanocrystals in a metastable crystalline form or even prepare the amorphous equivalent
of nanocrystals. However, this is not common in practice.
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Table 1. Commonly used and more recent methods for characterising nanocrystals.
Category CharacterisationMethod
Detection
Principle Information Data Type Variations
Sample
Requirements Considerations References
Solid state form
X-ray powder
diffraction (XRPD)
Diffraction of
x-rays from lattice
planes
Polymorphic form
(unique diffraction
peaks), amorphous
form (no peaks)
Diffractogram,
qualitative and
quantitative (degree
of crystallinity)
Hot stage XRPD to
analyse solid state
form as a function
of temperature
Powder, paste or
slurry form,
several sample
presentation setups
possible, amount
required depends
on setup
Anisotropic
particle shape
leads to preferred
orientation effects
(change in relative
intensities of
diffraction peaks)
[17]
Peak broadening
can occur as crystal
lattice size
decreases within
nanoscale range
Differential
scanning
calorimetry (DSC)
Change in heat
flow due to sample
changes during
heat/cooling
Polymorphic form
(melting
temperature,
crystallisation
temperature)
amorphous form
(glass transition
temperature),
crystallinity
(enthalpy of fusion,
enthalpy of
crystallisation, heat
capacity change at
glass transition
temperature)
Thermogram,
qualitative and
quantitative
Modulated
temperature DSC
to separate
overlapping
irreversible and
reversible thermal
events, ultrafast
heating
Powder form, few
milligrams
Destructive.
Results will be
different with open
or closed
(hermetically
sealed) pans
[18]
Infrared (IR)
spectroscopy
(mid-IR
spectroscopy)
Change in dipole
moment during
molecular
vibrations
Polymorphic form
(peak shifts and
relative intensities),
crystallinity
(broadening of
bands, peak shifts
and relative
intensities)
Spectrum, qualitative
and quantitative,
suitable for
multivariate analysis
Diffuse reflectance
IR (DRIFTS),
attenuated total
reflection (ATR),
microscope
Powder or tablet
form, depends on
sampling setup,
few milligrams.
Wet samples
usually
problematic.
Sample
preparation/measurement
can involve
pressure which can
induce solid state
transformations
[19,20]
Raman
spectroscopy
Change in
polarisability
during molecular
vibrations
Polymorphic form,
crystallinity
Spectrum, qualitative
and quantitative,
suitable for
multivariate analysis
Various sample
holders (within
spectrometer,
sampling probes,
microscope)
Powder or
suspension, few
milligrams
(usually).
Fluorescent
samples are
problematic.
Sample heating can
be problematic.
Samples can be in
aqueous medium.
[20–22]
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Table 1. Cont.
Category CharacterisationMethod
Detection
Principle Information Data Type Variations
Sample
Requirements Considerations References
Size and
morphology
Dynamic light
scattering (photon
correlation
spectroscopy)
Fluctuation of
Rayleigh scattering
of light associated
with Brownian
motion of
nanoparticles
Particle size,
particle size
distribution
Particle size
distribution (number
based mean particle
(hydrodynamic) size
(Z-average),
polydispersity index),
quantitative
Suspension with
suitable
concentration
Suitable only for
particles in
nanometre size
range
[23]
Viscosity of
suspension and
temperature affect
results
Scanning electron
microscopy (SEM)
Backscattering of
electrons
Topographical
information about
particles
Scanning electron
micrograph, particle
morphology, size
Elemental analysis
Dry sample
mounted on stage
condition setup
(vacuum),
microgram
requirement
Sample
preparation
destructive
[15]
Transmission
electron
microscopy
Transmission of
electrons
Density
information
Transmission
electron micrograph,
morphology of cross
sections, stabilizer-
nanocrystal
interaction
Embedded cross
section
preparation,
microgram
requirement
Sample
preparation
destructive
[24]
Surface properties
Zeta-potential
Dynamic
electrophoretic
mobility under
electric field
Surface charge
(zeta potential)
Zeta potential,
quantitative
Suspension with
suitable
concentration
[25]
Surface plasmon
resonance (SPR)
Changes in
refractive index in
the vicinity of a
planar sensor
surface
Surface adsorption
Spectrum, interaction
between stabiliser
drug crystals,
qualitative and
quantitative
Substrate on planar
surface sensor
required (not direct
measurement of
nanocrystals)
Careful sample
preparation
required
[26]
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Table 1. Cont.
Category CharacterisationMethod
Detection
Principle Information Data Type Variations
Sample
Requirements Considerations References
Drug delivery
Dissolution testing
Dissolved drug
analysed over time,
usually using UV
spectroscopy or
HPLC
Dissolution profile Solutionconcentration vs time
Paddle, flow
through cell
(with/without
membrane insert),
pharmacopeial/non
pharmacopeial
Separating
nanocrystals from
dissolution
medium can be
problematic
[14]
Fluorescence
microscopy
Fluorescence by
endogenous or
added
fluorophores
Localization of
nanocrystals in
relation to cells and
tissues
Fluorescence (and
nanocrystal) image
One or two photon
(two photon
fluorescence offers
inherent
confocality,
sub-micron spatial
resolution, deeper
penetration
in tissues)
fluorescence
Non-fluorescent
nanocrystals
require fluorphore
to physically
entrapped into
nanocrystals
Entrapment and
leakage of
fluorophore can be
difficult or
problematic
[17]
Non-linear Raman
microscopy
Change in
polarisability
during molecular
vibrations.
Label free
localisation of
particles
Intensity of CARS
shift (narrow band)
or spectrum,
(multiplex or broad
band). Most
commonly
qualitative. 2D or 3D
images.
Can be dry or
aqueous
suspension, in cell
cultures or tissue
samples
Coloured and
two-photon
fluorescent
samples can
interfere with
signal. Can be
coupled with other
nonlinear
phenomena such
as second
harmonic
generation or two
photon electronic
fluorescence
Label free. Optimal
lateral spatial
resolution
approximately
300–400 nm.
[21,27]
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Different nanocrystal manufacturing methods and conditions can affect the resulting solid
state form, and furthermore the thermodynamically stable polymorphic form depends on the
environmental conditions. For example, hydrate forms are generally more stable (and therefore
less soluble) in aqueous media and in some cases also humid conditions, and therefore if the drug
has the potential to form a hydrate form then the potential for conversion should be thoroughly
investigated during stability studies in different conditions. X-ray powder diffraction, differential
scanning calorimetry and vibrational spectroscopy (infrared and Raman) are the most commonly
used methods to establish and monitor the solid state form of nanocrystals (Table 1).
As mentioned earlier, the solid state properties of nanocrystals are affected by the production
method. With bottom-up techniques partial amorphousness is not uncommon, with detrimental
effects on the stability of the nanocrystals [28]. Liquid atomization based techniques, like spray
drying or electrospraying, are particularly prone to generating a final product in the amorphous form
(partially or fully), but full crystallinity can be achieved after production by annealing [29]. The
high shear stresses associated with wet ball milling and high pressure homogenization can induce
polymorphic changes, but if the milling or homogenization is performed in an aqueous environment
the water functions as a plasticizer (raises molecular mobility) and reduces the tendency for sustained
formation of amorphous material.
Ali et al. prepared hydrocortisone nanosuspensions by both wet-milling and microfluidic
nanoprecipitation [28]. With both methods, the particle sizes were approximately 300 nm, yet with
milling the product was crystalline, while precipitation resulted in a predominantly amorphous
product. In in vivo tests with rabbits, the bioavailability during ocular delivery was comparable with
both the formulations and when compared to drug solution almost doubled. Differences were clear
in stability tests: the crystalline wet-milled nanosuspension was stable for two months (unaltered
particle size), but the particle size of the amorphous precipitated nanosuspension had increased to
440 nm.
Lai et al. [13] formulated piroxicam nanocrystals with poloxamer 188 as a stabilizer by high
pressure homogenization. While the raw material was form I, the resulting nanocrystals were a
mixture of monohydrate and form III. The solubility of form I is 14.3 mg/L, while that of form III
is 17.0 mg/L. In this case the solubility was increased not only due to the smaller particle size, but
also due to the formation of the higher energy solid-state forms.
Pireddu et al. studied two different diclofenac sodium crystal forms for (trans)dermal drug
delivery [30]. Nanocrystals were produced by wet ball milling, with poloxamer 188 used as a
stabilizer. There were no significant differences between the particle size of the two polymorphs
when the same milling protocol was used, but differences in the stability of the particle size were
seen during 90 days of stability testing. The milling did not change the polymorphic form of the drug.
They calculated the crystallite size of the milled polymorphs based on XRPD peak width broadening
and found out that for polymorph 1, the crystallite size was around 90 nm while for polymorph
2 it was around 65 nm. In vitro penetration and permeation was studied with new born pig skin
using Franz diffusion cells. All the nanosuspension formulations improved the drug penetration
compared to a commercial gel formulation. Interestingly, though the two polymorphic forms differed
in drug permeation properties when administered as coarse suspensions, their nanosuspensions
behaved similarly.
4. Particle Size and Surface Properties
The size, size variation and shape of nanocrystals are related to efficient stabilization of
nanosuspensions [31] (Figure 1). The smaller the particle size, the higher the surface energy of the particles,
which promotes aggregation. As a result, careful stabilizer selection is crucial when formulating
nanocrystals [7,32]. Very rarely, self-stabilization of nanocrystals with any additional stabilizer
is possible. This has been demonstrated with 2-devinyl-2(1-hexyloxyethyl)-pyropheophorbide
nanocrystals, whose zeta potential, at ´40 mV, is sufficient for stabilization [33].
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via hydrophilic-hydrophobic interactions and enhance the wetting of nanocrystals. The classical 
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stabilization with, for example, polymers or nonionic long chain surfactants. Steric stabilization can 
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surfactants and if the system is stabilized only by electrostatic forces, the eigenvalue of the zeta 
potential should be higher than 30 mV. Electrostatic stabilization can be vulnerable if the liquid 
environment is changed, for example by the addition of ionic species. It is also useful to keep in mind 
that drying also alters the ionized state, which can itself affect the level of electrostatic stabilization.  
Surface plasmon resonance (SPR) analysis has been utilized in interaction studies between solid 
drug surfaces and aqueous stabilizer solutions [26]. Five structurally different PPO/PEO block  
co-polymers were used as stabilizers for indomethacin nanocrystals, and the affinities of stabilizers 
on solid drug surfaces were determined by SPR and contact angle measurements. Both techniques 
showed a similar order of efficiency of binding to the solid surfaces (Figure 2). The interaction 
measurements were compared to successful formation of nanocrystals with the same drug-stabilizer 
systems by wet ball milling. It was concluded that interaction forces cannot alone determine the most 
efficient stabilizer, but moderate affinity with longer PEO chains, which are efficient for steric 
stabilization, formed best nanosuspensions. 
 
Figure 2. Binding efficiencies of different poloxamers for the indomethacin layers on SPR (grey bars) 
and contact angle values (black line) for 0.1% (w/v) stabilizer solutions measured on indomethacin 
compression surfaces (modified from [26]). 
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Though the main role of the stabilizers in anocrystallization is t st bilize th nanoparticles that
have formed, most stabilizers in use also enhance permeation to some degree or otherwise influence
active transport systems. Accordingly, by careful formulation, not only the dissolution but also
the permeation may be actively enhanced with the presence f the stabilizers in nanocrystal based
formulatio s [34].
Most stabilizers are amphiphilic molecules which attach to newly formed drug particle surfaces
via hydrophilic-hydrophobic interactions and enhance the wetting of nanocrystals. The classical
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that drying also alters the ionized state, which can itself affect the level of electrostatic stabilization.
Surface plasmon resonance (SPR) analysis has been utilized in interaction studies between solid
drug surfaces and aqueous stabilizer solutions [26]. Five structurally different PPO/PEO block
co-polymers were used as stabilizers for indomethacin nanocrystals, and the affinities of stabilizers
on solid drug surfaces were determined by SPR and contact angle measurements. Both techniques
showed a similar order of efficiency of binding to the solid surfaces (Figure 2). The interaction
measurements were compared to successful formation of nanocrystals with the same drug-stabilizer
systems by wet ball milling. It was concluded that interaction forces cannot alone determine the
most efficient stabilizer, but moderate affinity with longer PEO chains, which are efficient for steric
stabilization, formed best nanosuspensions.
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5. Dissolution of Nanocrystals: Apparent Solubility and Supersaturated State
Thermodynamic solubility is the solubility of the most stable crystalline form of the drug in
a given medium at defined temperature and pressure. Solubility can temporarily be higher than
the thermodynamic solubility, which may be observed with, for example higher energy amorphous
forms, metastable polymorphic forms, or nanosized drug particles. This elevated solubility has been
described with varying terms, such as kinetic or apparent solubility, with the latter term being used in
this review. Since the apparent solubility with nanosized particles is higher than the thermodynamic
solubility of the material, dissolution of nanocrystalline material is likely to lead to a supersaturated
solution, also known as the “spring effect”.
Ige et al. studied the saturation solubility of fenofibrate nanocrystals [35], which had been
reduced in size from 80 µm (bulk drug) to 460 nm (nanocrystals). The thermodynamic solubility of
the bulk drug in aqueous 0.5% and 1% sodium dodecyl sulfate solution, was 6.02 and 23.54 µg/mL,
respectively, while the corresponding values for drug nanocrystals were 67.51 and 107 µg/mL,
respectively.
In another study, the intrinsic dissolution rates and surface concentrations with differently
sized indomethacin nanocrystals with two different poloxamer stabilizers were studied [6]. Intrinsic
dissolution rates were measured with a channel flow system. The intrinsic dissolution rates were
affected by both the particle size and the stabilizer. With the smallest nanocrystals (580 nm), the
intrinsic dissolution rate with poloxamer F68 as a stabilizer was 0.50 µg/min/mm2, while that
for poloxamer F127 was 0.31 µg/min/mm2. The dissolution rate of bulk indomethacin was also
measured, and was much lower at 0.05 µg/min/mm2. Surface concentrations have also been
measured with UV-imaging [6]. Again, differences in concentrations were affected by both particle
size and stabilizer (Table 2). For example, with equally sized nanocrystals (580 nm), the surface
concentration after 10 min of dissolution was 28.7 mg/L with Pluronic F 68 while with Pluronic F127
the corresponding value was 22.1 mg/L. With both stabilizers, the difference with bulk indomethacin
was dramatic; the surface concentration with bulk indomethacin was only 2.1 mg/L.
Table 2. Surface concentrations after 10 min of dissolution of indomethacin compressed surfaces
(modified from [6]).
Sample
Concentration/mg/L
Distance from the Dissolution Surface
0 mm 2 mm 3 mm
Nanocrystals with Pluronic F 68, particle size 580 nm 28.7 11.7 5.8
Microcrystals with Pluronic F 68 11.4 4.0 2.6
Nanocrystals with Pluronic F127, particle size 580 nm 22.1 9.4 4.3
Microcrystals with Pluronic F127 17.1 7.6 4.0
Bulk indomethacin 2.1 0.3 0.0
As already stated in the Table 1, dissolution and solubility testing of nanocrystals can
be demanding due to the separation problems: undissolved nanocrystals should be able to
be separated from the dissolution medium before concentration determinations. For that both
ultracentrifugation [7] and filtration [26] or their combination [19] has been used. Both methods
has their own limitations [14]. In filtering the drug may interact with filter material and/or
smallest particles can pass through the filter. On the other hand, in centrifugation due the long
centrifugation time and increased temperature drug may be absorbed to tube material and/or also
further dissolution may occur during the process [14]. Liu with coworkers [14] studied impact of
ultracentrifugation and filtration on the dissolution results. Indomethacin had interactions both with
one filter type tested as well as with centrifuge tube material, but it was concluded that by careful
selection of filter type the filter was still the best choice in that study. Undissolved drug particles
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in the sample can be recognized by utilizing more than one wavelength in the analysis. Sarnes with
colleagues [6] determined drug concentrations with solubility testing of nanocrystalline samples with
UV-spectrophotometer. The drug concentration determinations were done with the wavelength were
the drug had its absorption maximum, but the absence of undissolved particles were confirmed with
the wavelength were the absorbance of the excipient and drug was negligible.
Eventually, precipitation may sooner or later occur until the concentration equals the
thermodynamic solubility. Furthermore, changes in the composition and pH of the solution such as
in the gastrointestinal tract will affect solubility and hence the tendency for crystallisation. In order to
improve the bioavailability in vivo, the supersaturated state should be maintained and precipitation
hindered. Some polymers, such as polyvinyl pyrrolidone (PVP) [36], methacrylate co-polymers [37],
hydroxypropyl methylcellulose (HPMC) [38], and hydroxypropyl methylcellulose acetate succinate
(HPMC-AS) [38] are effective at maintaining (or at least helping to maintain) supersaturation.
This is termed the “parachute effect”. Solid dispersions, especially where the amorphous drug is
dispersed on a molecular level within the polymeric crystallization inhibitor, are well established
as parachute promoters. However, the permeation from supersaturated solutions may be hindered
by the precipitation inhibitor, as is the case often with solubilizing agents, when the drug favors
the micelles instead of permeation [39].
The parachute effect of the polymer can be due to a combination of mechanisms [40–43].
First, the polymers can themselves increase the thermodynamic solubility of the drug (also known
as the co-solvency effect) which reduces supersaturation and consequently the thermodynamic
driving force for crystallisation (importantly, this also leads to an additional spring effect with the
polymer) [44]. Through drug-polymer complexes in solution via electrostatic bonds, van der Waals’
forces or hydrogen bonding, even the addition of small amounts (0.1%–0.25% w/w) of polymers such
as PVP and HPMC to solution can significantly increase the aqueous solubility [45]. Second, polymers
adsorbed on solid surfaces (e.g., with nanocrystals) can block the interaction of already dissolved
drug molecules with crystal surfaces and thereby crystal growth. Electrostatic bonds, van der Waals’
forces or hydrogen bonding can all affect the interaction between the polymer and crystal faces, and
therefore the degree of crystal growth inhibition. Third, the viscosity of the polymer solution may
also inhibit the diffusion of the molecules which limits crystal growth [44].
Ghosh et al. [8] formulated nanocrystals from a poorly soluble drug with TPGS or TPGS
with a co-stabilizer (HPMC, PVP, poloxamers). During in vivo analysis with dogs, the AUC value
was nine times higher and Cmax five times higher with nanosuspension than with coarse drug
formulations. The physical stability during storage with TPGS alone was considerably lower than
for the mixed systems.
Ueda et al. [46] studied the maintenance of supersaturation with amorphous and nanocrystalline
formulations of carbamazepine. For in depth analysis of supersaturation, they conducted real-time
monitoring with NMR spectroscopy of the dissolved carbamazepine with both amorphous and
nanocrystalline drug in supersaturated solution. Based on 1H-NMR measurements, the dissolved
concentrations for nanocrystalline carbamazepine were nearly constant for 50 h. The authors
concluded that nanoparticle formation lowered the degree of supersaturation, leading to a relatively
stable supersaturated solution of carbamazepine. The presence of nanoparticles also suppressed the
formation of large precipitates. With spray dried amorphous carbamazepine, the initial concentration
was higher but it then dropped below the concentration of the nanocrystalline sample, indicating
that the higher supersaturation was more kinetically unstable with fast precipitation/crystallization
of large microparticles. The particle size of nanocrystals in this study was approximately 150 nm.
6. Drug Absorption from Nanocrystalline Formulations
As mentioned above, drug absorption is a function of both solubility and permeability. Solubility
is typically negatively correlated to lipophilicity. Dissolution from nanocrystals is followed by
permeation of the dissolved drug across the gastrointestinal wall (in the same way as drug from a
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solution formulation). In addition to increase permeation due to higher dissolved concentrations,
stabilizers themselves interact with cells and epithelial cell layers to enhance permeation. However,
this requires the simultaneous presence of both drug and stabilizer in the presence of cells, which
may not always be the case.
Li with colleagues [47] studied the effect of drug physicochemical properties on oral
bioavailability. They studied five different drugs and nanocrystals were produced with the same
stabilizer, poloxamer 188, by high pressure homogenization. Particle size with all the tested drugs
was from 430 to 460 nm. The AUC values for nanocrystals were in all the cases 1.4–7.2 times higher as
compared to drug microsuspensions after oral administration of suspensions to rats. Melting point,
log P value and polar surface area affected drug absorption and drugs with low melting point, log
P value approximately 5 and polar surface area value between 50 and 60 showed higher absorption
with the same sized nanocrystals.
Many stabilizers used for nanocrystal products (vitamin E TPGS, poloxamers, polysorbates) are
also P-gp inhibitors [12]. PEG chain length (between 200–6000 Da) in TPGS may affect the inhibition
activity and the best inhibition is reached with PEG chain lengths of 1100–1500 Da [48].
In some cases, nanocrystals can be taken up by cells (e.g., [21]). This may be desirable (e.g., with
cancer cell targeting) or undesirable (unpredictable pharmacokinetic profiles, see below). Uptake
will vary between cell types and their phagocytotic/endocytotic potential, as well as nanocrystal
properties such as size, morphology, stabilizer type, and surface charge. The wide selection of
possible nanocrystal formulations, and potential importance highlights the need, in some cases, for
an understanding of the nanocrystal behaviour on the cellular and tissue levels [49].
Chen and Li [34] studied the cellular uptake mechanism of paclitaxel nanocrystals. They found
out that nanocrystals were internalized by KB cells with higher concentrations than solubilized
formulations. They also concluded that drug nanocrystals were possible to take up as solid
particles probably via endocytosis. However, the surface layer of the nanocrystals affected the
uptake. Based on confocal imaging and temperature dependent internalization it was concluded that
endocytosis is probably responsible for the nanocrystal uptake by cells. Accordingly, nanocrystalline
chemotherapeutic formulation can possibly form intracellularly lethal microenvironment for the cell
when the drug nanocrystals are slowly dissolved inside the cells. This can be difficult to reach with
solubilized drug delivery systems. The mean particle size in this study was from 230 nm to 280 nm.
The ability of TPGS stabilized paclitaxel nanocrystals to reverse P-glycoprotein drug-resistance
in P-gp overexpressing H460 cancer cells was evaluated by Gao with colleagues [50]. They found out
that TPGS as a stabilizer on paclitaxel nanocrystals efficiently reduced drug resistance of the studied
cells. It is known that due to the EPR effect, drug nanoparticles can accumulate after intravenous
injection in the tumor tissues [51]. But therapeutic efficacy is limited by overexpressing MDR related
proteins like P-gp in resistant tumours. It has been shown that nanosized materials can be taken up
via endocytosis by cells, but after dissolution into cellular cytoplasm they can be pumped out by P-gp
efflux system [52]. Hence, utilization of simultaneous lowering of P-gp activity with endocytosis of
nanoparticles can increase the therapeutic efficiency, like was the case with TPGS coated paclitaxel
nanocrystals [50]. Drug and P-gp inhibitor should be at the same time inside the cells. This was not
realized when TPGS was given in solution together with free paclitaxel molecules [53], but with TPGS
coated paclitaxel nanocrystals it worked [50].
While electron microscopy and fluorescence imaging are the two main established methods
to image the physical interaction of nanoparticles with cells [49,54], including their uptake and
localization within the cells they have some drawbacks (e.g., lack of chemical specificity and inability
to probe live cells with electron microscopy), and complications with fluorescent labels, including
label leaching and overestimation of nanocrystal internalisation when the fluorescent labels but not
necessarily the nanocrystals themselves enter the cells [55,56]. Thus, it is worth considering novel
analytical techniques in this context.
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Confocal Raman microscopy and coherent anti-Stokes Raman scattering (CARS) microscopy
are relatively novel label-free, chemically specific and non-destructive methods with potential for
label-free imaging of nanocrystal-cell interactions. With these techniques submicron particles may be
detected provided they have a sufficiently strong Raman or CARS signal (the resolution and speed
is better for the inherently confocal CARS technique, while chemical specificity is better for Raman
microscopy) [27,57,58].
In a proof of concept study that also had clinical relevance [21], Darville et al. imaged
the fate of nonfluorescent nano/micro crystals of the antipsychotic prodrug, paliperidone
palmitate, in macrophage cell cultures and histological sections using CARS microscopy (Figure 3).
The commercially available product Xeplionr is a long-acting aqueous suspension for intramuscular
injection with a measured median volume based equivalent sphere diameter of approximately
1000 nm and a DV ,10 of approximately 450 nm.
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Figure 3. Interactions between paliperidone palmitate (PP) nanocrystals and RAW 264.7 macrophages 
imaged by CARS after 2 (a–d) and 24 h (e–h). Imaged is performed using CARS signal at 2860 cm−1 
and fluorescently dyed cell membranes are imaged using TPEF. (a,e) low and high magnification 
brightfield imaging; (b,f) forward-CARS (red)/TPEF (green) merged micrographs of stained/fixed cells; 
In (c,g) intracellular PP nanocrystals are seen in orthogonal projections of z-stacked F-CARS/TPEF 
overlays; (d,h) show 3D-reconstructions of the z-stacked F-CARS/TPEF overlays. White arrows indicate 
PP-NC adsorbed onto cell surface and black arrows phagocytosed PP-NCs. (From [21], reprinted from 
Elsevier with permission).  
The active species, paliperidone, is esterified with the palmitate moiety to reduce solubility and 
associated dissolution rate, thereby sustaining the release of the paliperidone. In vivo, complex and 
variable pharmacokinetic profiles have been observed [59] and in rats the formation of granulomatous 
tissue in the region of the intramuscular nanocrystals has been observed. The inflammatory response 
led to particle agglomeration, phagocytosis and radial angiogenesis in the rats resulting in multiphasic 
systemic absorption of the paliperidone being observed [21]. CARS microscopy was used to investigate 
the fate of the paliperidone palmitate nanocrystals with macrophage cells in vitro and histological 
sections in situ in some detail. The nanocrystals were imaged in both fixed and live cells using the 
CH2 stretching resonance at 2845 cm−1, mainly associated with the palmitate moiety (the nanocrystals 
were resolved from endogenous lipid in this case through geometrical differences, and an otherwise 
weak lipid signal from the cells was used, although with other drugs a CARS resonance resolved 
from lipid signals could be used for chemical specificity). In tissue sections, intracellular nanocrystals 
were imaged within the granulomatous tissue. 
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Drug nanocrystals are a highly feasible option for enhancing drug release profiles with poorly 
soluble drugs. However, in order for nanocrystal formulations to be successful in vivo, a thorough 
understanding of their critical quality attributes from the production step to the end product 
performance is required. With nanocrystal formulations the physical stability should be monitored 
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resolved from lipid signals could be used for chemical specificity). In tissue sections, intracellular
nanocrystals were imaged within the granulomatous tissue.
7. Conclusions
Drug nanocrystals are a highly feasible option for enhancing drug release profiles with poorly
soluble drugs. However, in order for nanocrystal formulations to be successful in vivo, a thorough
understanding of their critical quality attributes from the production step to the end product
performance is required. With nanocrystal formulations the physical stability should be monitored
carefully. Solubility properties needs to be known as well as their effect on supersaturation. Even
more important is the control of precipitation after rapid dissolution and supersaturation in vivo,
in order to promote fast and efficient permeation. This can be reached for example by utilization
of excipients promoting the maintenance of supersaturation in the formulations. Finally, reaching
reliable in vitro in vivo correlation should be confirmed and understood on a mechanistic level: the
high bioavailability of nanocrystal formulations is based on careful formulation design, suitable
analysis methods and recognition of the most important critical quality attributes.
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